This report was first published by Endpoints News. To see the original version, click here
Pfizer said Tuesday that the monthly injection that was one of the cornerstones of its $10 billion buyout of Metsera allowed obesity patients to lose up to 10.5% of their weight, on a placebo-adjusted basis, after just over six months.
Shareholders were unimpressed with the data, appearing to doubt whether the results were good enough to vindicate Pfizer’s acquisition of the obesity-focused biotech. Pfizer’s shares $PFE were down 3% in early trading, on the same day it reported its full-year 2025 earnings.
您已阅读13%（600字），剩余87%（4127字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。